The 2023 Impact of Inflammatory Bowel Disease in Canada: Executive Summary

Joseph W Windsor¹, M Ellen Kuenzig^{2

3}, Sanjay K Murthy^{4

5}, Alain Bitton⁶, Charles N Bernstein^{7

8}, Jennifer L Jones⁹, Kate Lee¹⁰, Laura E Targownik¹¹, Juan-Nicolás Peña-Sánchez¹², Noelle Rohatinsky¹³, Sara Ghandeharian¹⁰, James H B Im^{2

3}, Tal Davis^{2

3}, Jake Weinstein^{2

3}, Quinn Goddard¹, Eric I Benchimol^{2

3

14

15

16}, Gilaad G Kaplan¹

Affiliations

¹ Departments of Medicine and Community Health Sciences, University of Calgary, Calgary, Alberta, Canada.
² SickKids Inflammatory Bowel Disease Centre, Division of Gastroenterology, Hepatology and Nutrition, The Hospital for Sick Children, Toronto, Ontario, Canada.
³ Child Health Evaluative Sciences, SickKids Research Institute, The Hospital for Sick Children, Toronto, Ontario, Canada.
⁴ Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada.
⁵ The Ottawa Hospital IBD Centre, Ottawa, Ontario, Canada.
⁶ Division of Gastroenterology and Hepatology, McGill University Health Centre IBD Centre, McGill University, Quebec, Canada.
⁷ Department of Internal Medicine, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada.
⁸ University of Manitoba IBD Clinical and Research Centre, Winnipeg, Manitoba, Canada.
⁹ Departments of Medicine, Clinical Health, and Epidemiology, Dalhousie University, Halifax, Nova Scotia, Canada.
¹⁰ Crohn's and Colitis Canada, Toronto, Ontario, Canada.
¹¹ Division of Gastroenterology and Hepatology, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada.
¹² Department of Community Health and Epidemiology, University of Saskatchewan, Saskatoon, Saskatchewan, Canada.
¹³ College of Nursing, University of Saskatchewan, Saskatoon, Saskatchewan, Canada.
¹⁴ ICES, Toronto, Ontario, Canada.
¹⁵ Department of Paediatrics, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.
¹⁶ Institute of Health Policy, Management and Evaluation, Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada.

PMID: 37674500
PMCID: PMC10478799
DOI: 10.1093/jcag/gwad003

Review

The 2023 Impact of Inflammatory Bowel Disease in Canada: Executive Summary

Joseph W Windsor et al. J Can Assoc Gastroenterol. 2023.

. 2023 Jun 1;6(Suppl 2):S1-S8.

doi: 10.1093/jcag/gwad003. eCollection 2023 Sep.

Authors

Affiliations

¹ Departments of Medicine and Community Health Sciences, University of Calgary, Calgary, Alberta, Canada.
² SickKids Inflammatory Bowel Disease Centre, Division of Gastroenterology, Hepatology and Nutrition, The Hospital for Sick Children, Toronto, Ontario, Canada.
³ Child Health Evaluative Sciences, SickKids Research Institute, The Hospital for Sick Children, Toronto, Ontario, Canada.
⁴ Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada.
⁵ The Ottawa Hospital IBD Centre, Ottawa, Ontario, Canada.
⁶ Division of Gastroenterology and Hepatology, McGill University Health Centre IBD Centre, McGill University, Quebec, Canada.
⁷ Department of Internal Medicine, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada.
⁸ University of Manitoba IBD Clinical and Research Centre, Winnipeg, Manitoba, Canada.
⁹ Departments of Medicine, Clinical Health, and Epidemiology, Dalhousie University, Halifax, Nova Scotia, Canada.
¹⁰ Crohn's and Colitis Canada, Toronto, Ontario, Canada.
¹¹ Division of Gastroenterology and Hepatology, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada.
¹² Department of Community Health and Epidemiology, University of Saskatchewan, Saskatoon, Saskatchewan, Canada.
¹³ College of Nursing, University of Saskatchewan, Saskatoon, Saskatchewan, Canada.
¹⁴ ICES, Toronto, Ontario, Canada.
¹⁵ Department of Paediatrics, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.
¹⁶ Institute of Health Policy, Management and Evaluation, Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada.

PMID: 37674500
PMCID: PMC10478799
DOI: 10.1093/jcag/gwad003

Erratum in

Correction to: The 2023 Impact of Inflammatory Bowel Disease in Canada: Executive Summary.
[No authors listed] [No authors listed] J Can Assoc Gastroenterol. 2023 Nov 13;6(6):255. doi: 10.1093/jcag/gwad038. eCollection 2023 Dec. J Can Assoc Gastroenterol. 2023. PMID: 38106483 Free PMC article.

Abstract

The burden of inflammatory bowel disease (IBD) (i.e., associated direct and indirect costs, prevalence of disease, personal impact to the individual and to caregivers) continues to increase in Canada. The prevalence of IBD has increased since Crohn's and Colitis Canada's 2018 Impact of IBD report from an estimated 270,000 Canadians living with IBD in 2018 to an estimated 322,600 Canadians living with IBD today in 2023. Consequently, associated costs of IBD have also dramatically increased from an estimated $2.57 billion in 2018 to an estimated $5.38 billion in 2023; this increase is due to multiple factors including increased prevalence of disease, inflation, and additional identified factors (e.g., presenteeism, costs of childcare). Beyond the economic impact of IBD, these diseases have a significant impact on people living with the disease and their caregivers, including different presentations of disease, different commonly associated extra-intestinal manifestations or comorbid conditions, and different barriers to accessing care. In this supplementary issue, we review: Evolving trends in the epidemiology of IBD; updated estimates of indirect and direct costs (including out-of-pocket costs) associated with IBD; information specific to IBD in children, adolescents, and seniors; issues related to IBD pertaining to sex and gender; information specific to risks associated with COVID-19 and cancer related to IBD; an overview of current treatments for IBD; and evolving care models, including access to care.

Keywords: Comorbidities; Crohn’s disease; Issues affecting the IBD community; Treatment; Ulcerative colitis.

PubMed Disclaimer

Conflict of interest statement

M.E.K. is a member of the Scientific and Medical Advisory Council of Crohn’s and Colitis Canada. S.K.M. has previously participated in advisory board meetings for AbbVie, Janssen, Takeda, Pfizer, Shire and Ferring and as a speaker at educational events sponsored by Janssen, AbbVie and Pfizer. E.I.B. holds the Northbridge Financial Corporation Chair in Inflammatory Bowel Disease, a joint Hospital-University Chair between the University of Toronto, The Hospital for Sick Children, and the SickKids Foundation. He has acted as a consultant for the Dairy Farmers of Ontario and McKesson Canada for matters unrelated to medications used to treat inflammatory bowel disease. He is Past Chair of the Scientific and Medical Advisory Council of Crohn’s and Colitis Canada and Editor-in-Chief of the Journal of the Canadian Association of Gastroenterology (JCAG). A.B. has participated in advisory boards with AbbVie, Janssen, Takeda, McKesson, BioJamp, Bristol Myers Squibb. He is on the speaker’s panel for Janssen, Takeda, Abbvie and has participated in educational activities supported by Viatris, Fresenius Kabi, and Amgen. C.B. is supported in part by the Bingham Chair in Gastroenterology. He is on Advisory Boards for AbbVie Canada, Amgen Canada, Bristol Myers Squibb, JAMP Pharmaceuticals, Janssen Canada, Lilly Canada, Pfizer Canada, Roche Canada, Sandoz Canada, Takeda Canada. He is a Consultant for Mylan Pharmaceuticals and Takeda. He has received educational grants from AbbVie Canada, Pfizer Canada, Takeda Canada, Janssen Canada, and Bristol Myers Squibb Canada. He is on the speaker’s panel for AbbVie Canada, Janssen Canada, Pfizer Canada, and Takeda Canada. Received research funding from AbbVie Canada, Pfizer Canada, Sandoz Canada. J.L.J. has received honoraria for speaking and consulting for AbbVie, Janssen, Pfizer, Shire, and Takeda. She is the co-chair elect of the Scientific and Medical Advisory Council of Crohn’s and Colitis Canada. K.L. has received honoraria from AbbVie Corporation and Bristol Myers Squibb Canada. L.E.T. has received research funding from AbbVie Canada, Takeda Canada, Sandoz Canada, Amgen Canada, Gilead Canada, Roche Canada and Pfizer Canada, and has been on Advisory Boards for Janssen Canada, AbbVie Canada, Takeda Canada, Pfizer Canada, Merck Canada, Roche Canada, Sandoz Canada, Organon Canada, Fresesnius Kabi Canada, Eli Lilly Canada, and Amgen Canada. She is a member of the Scientific and Medical Advisory Council of Crohn’s and Colitis Canada. G.G.K. has received honoraria for speaking or consultancy from AbbVie, Janssen, Pfizer, and Takeda. He has received research support from Ferring, Janssen, AbbVie, GlaxoSmith Kline, Merck, and Shire. He has been a consultant for Gilead. He shares ownership of a patent: TREATMENT OF INFLAMMATORY DISORDERS, AUTOIMMUNE DISEASE, AND PBC. UTI Limited Partnership, assignee. Patent WO2019046959A1. PCT/CA2018/051098. 7 Sept. 2018. He is a member of the Scientific and Medical Advisory Council of Crohn’s and Colitis Canada. The other authors declared no conflict of interest.

References

1. Benchimol EI, Bernstein CN, Bitton A, et al. . The impact of Inflammatory Bowel Disease in Canada 2018: A scientific report from the Canadian gastro-intestinal epidemiology Consortium to Crohn’s and Colitis Canada. J Can Assoc Gastroenterol 2019;2:S1–5. - PMC - PubMed
1. Kuenzig ME, Fung SG, Marderfeld L, et al. ; InsightScope Pediatric IBD Epidemiology Group. Twenty-first century trends in the global epidemiology of pediatric-onset Inflammatory Bowel Disease: Systematic review. Gastroenterology 2022;162:1147–59.e4. - PubMed
1. Windsor JW, Hracs L, Gorospe J, et al. The global evolution of inflammatory bowel disease across four epidemiologic stages: A systematic review of incidence and prevalence studies over the past century. Gastroenterology. In press.
1. Kuenzig ME, Windsor JW, Barrett L, et al. . Crohn’s and Colitis Canada’s 2021 impact of COVID-19 and Inflammatory Bowel Disease in Canada: Executive summary. J Can Assoc Gastroenterol 2021;4:S1–9. - PMC - PubMed
1. Kaplan GG, Windsor JW.. The four epidemiological stages in the global evolution of inflammatory bowel disease. Nat Rev Gastroenterol Hepatol 2021;18:56–66. - PMC - PubMed

Publication types

Actions

LinkOut - more resources

Full Text Sources
- Europe PubMed Central
- PubMed Central
Medical
- ClinicalTrials.gov

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

The 2023 Impact of Inflammatory Bowel Disease in Canada: Executive Summary

Affiliations

The 2023 Impact of Inflammatory Bowel Disease in Canada: Executive Summary

Authors

Affiliations

Erratum in

Abstract

Conflict of interest statement

References

Publication types

LinkOut - more resources

Full Text Sources

Medical